RxDoctor Payments Data

Lawrence Solomon, MD

Cardiovascular Disease · Fishkill, NYNPI 1396719936

Payments from drug & device makers

$1,354in general payments, 2019–2025

Across 68 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$295
  • Novartis$261
  • Astellas Pharma US Inc$218
  • AstraZeneca$150
  • Boehringer Ingelheim$100
  • E.r. Squibb & Sons, L.L.C.$75
  • plus $256 from 7 others

What the payments were for

  • Food & beverage$1,14284%
  • Education$21216%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,354 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$397,935
Medicare patients
2,054
Services billed
7,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban522$720,867
XareltoRivaroxaban137$159,937
Repatha SureclickEvolocumab82$100,994
EntrestoSacubitril/Valsartan69$95,694
FarxigaDapagliflozin Propanediol78$87,314
Praluent PenAlirocumab68$54,613
NexlizetBempedoic Acid/Ezetimibe60$46,689
JardianceEmpagliflozin29$30,526
Rosuvastatin Calcium992$18,011
Atorvastatin Calcium1,231$17,082
Metoprolol Succinate766$15,143
Ezetimibe370$15,016
VascepaIcosapent Ethyl19$12,330
Valsartan171$6,494
Dofetilide17$6,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$720,867522 claims
Johnson & JohnsonXarelto$28$159,937137 claims
NovartisEntresto$261$95,69469 claims
AstraZenecaFarxiga$150$87,31478 claims
Boehringer IngelheimJardiance$100$30,52629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Fishkill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →